The FDA approved Abbott's Aveir single-chamber leadless pacemaker for the treatment of slow heart rhythms.
The pacing system is implanted directly inside the heart's right ventricle via a minimally invasive procedure to treat slower-than-normal heart rates, according to an April 4 news release. It allows cardiologists to measure electrical signals and determine the correct device placement before final implantation through its mapping capabilities.
"The Aveir VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options," said Randel Woodgrift, senior vice president of cardiac rhythm management at Abbott. "Our goal is to continue to build on the success of Aveir to provide more first-of-their-kind products in the future, revolutionizing how abnormal heart rhythms are treated."